BELLUS Health Inc  

(Public, TSE:BLU)   Watch this stock  
Find more results for BLU
1.12
+0.02 (1.82%)
Delayed:   1:55PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.12 - 1.12
52 week 0.32 - 1.30
Open 1.12
Vol / Avg. 5,848.00/31,437.00
Mkt cap 106.24M
P/E     -
Div/yield     -
EPS -0.03
Shares 47.43M
Beta 2.09
Inst. own     -

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -149.05% -43.04%
Operating margin -185.05% -71.68%
EBITD margin - -145.79%
Return on average assets -12.34% -3.83%
Return on average equity -28.91% -8.92%
Employees 9 -
CDP Score - -

Address

275 Armand-Frappier Blvd.
LAVAL, QC H7V 4A7
Canada
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)

Website links

Description

BELLUS Health Inc. (BELLUS Health), is a development-focused healthcare company. BELLUS Health is focusing on products, which provides health solutions and address medical needs. The Company�s product portfolio includes two pharmaceutical drug candidates and one commercial stage nutraceutical product, which include KIACTA, BLU8499 and VIVIMIND. BELLUS Health� primary focus is on advancing KIACTA, a treatment for AA amyloidosis through a pivotal Phase III Confirmatory Study. In August 2013, BELLUS Health Inc. acquired Thallion Pharmaceuticals Inc.